Podcast Index
Explora podcasts por categoría, abre episodios recientes y descarga audio para escucharlo sin conexión.
Smart Biotech Scientist | The CMC and Bioprocessing Podcast for Process Development and Manufacturing Leaders
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
Las noticias en Onda Cero
OndaCero
Calming Anxiety | Guided Meditation, Sleep Hypnosis & Panic Attack Relief
Martin Hewlett - Calming Anxiety
Power Pizza
Nick Lorro Sio
The AV Life
Tim Van Woeart
Stoicism Philosophy
Stoicism Philosophy
Anime S-Tier
Anime S-Tier
True Crime Sussurrado
OBOMEDIA ENTERTAINMENT
アソビガタリ
赤井、藤本、兒玉
【本・再放送】英語の語源が身につくラジオ (heldio)
堀田隆一
RHAP: We Know Reality TV
Friends of Rob Has a Podcast
Manna: Daily Scripture Meditations
Reformed Perspective
بودكاست ركن الحلبة
بودكاست ركن الحلبة
First15 Devotional
First15
Studio Allsvenskan
Nyheter24
Be Calm on Ahway Island | Bedtime Stories & Meditations for Kids
Sheep Jam Productions
National Day Spotlight | Presented By National Day Calendar
National Day Calendar
SBS Indonesian - SBS Bahasa Indonesia
SBS
SBS Ukrainian - SBS Українською
SBS
The Stacking Benjamins Show
Joe Saul-Sehy and Josh ‘OG’ Bannerman, CFP
Nerdaties
Nerdaties
Capital, la Bolsa y la Vida
Capital Radio
LessWrong (30+ Karma)
LessWrong
Hartford News Today | 2 Min News | The Daily News Now!
The Daily News Now!
The Daily Suncast
The Daily Sun
The Community Lounge
Steve McLeod
Radio Inagro
The Podcast Planet
The Agenda
The Alternative Commentary Collective
Radio Granada
Cadena SER
Radio Jódar
Cadena SER
SBS Pashto - اس بي اس پښتو
SBS
Les grands dossiers de l'Histoire par Franck Ferrand
Radio Classique
«Разбудите Даля» на Эльдорадио
Эльдорадио
Meet Cute Originals
Meet Cute
Quién como Dios?
Quién como Dios?
The Peoples Voice Podcast
Trey Evans
Giornale Orario di RTL 102.5
RTL 102.5 Hit Radio s.r.l.
Todo
David Brühlmann - CMC Development Leader, Bioprocess Expert, Business Strategist
The cell and gene therapy industry faces massive hurdles—cost, scalability, and the need for highly skilled operators have historically limited the reach of these transformative treatments. advanced therapy medicinal pro...
What if the simple act of opening an incubator could undermine the consistency of your cell therapy manufacturing process? Unlike traditional biologics, the moment cells leave their incubator, subtle shifts in temperatur...
Digital transformation in biotech is no longer just about adopting new tools, it's about building a foundation where automation, data standardization, and AI integration actually lead to real value and long-term success....
Despite cutting-edge equipment and brilliant minds, biotech labs often find half their data trapped in difficult-to-access spreadsheets or isolated in silos, making true digital transformation a major, industry-wide hurd...
Host David Brühlmann returns for a focused solo episode to provide an honest, data-driven perspective on the evolving landscape of host selection for biologics manufacturing. Building on part one, David reviews five alte...
In this solo episode, David Brühlmann explores the evolving landscape of biologic manufacturing platforms beyond CHO (Chinese hamster ovary) cells. Drawing from previous interviews with platform pioneers and rigorous dat...
Funding novel therapeutics isn’t just “harder than ever”—the rules have changed entirely. The wild rush of capital into early-stage biotech during 2020–2021 gave way to a drought, making investor priorities sharper and s...
Strong science alone won’t get your biotech startup funded—investors are sizing up much more than just your molecule.Michael Rome, who leads therapeutics investing at Foresite Capital, brings a rare dual lens as both sci...
What happens between scientific discovery and clinical trials? For too many drug candidates, the answer is “failure”—not because the idea lacked merit, but because the critical handoff between discovery and IND-enabling ...
The gap between a “drug” and a true “product” is where many therapies fail.Milan Tomic, biotech veteran, GMP manufacturing expert, and founder of Albrem, has spent 30 years turning promising science into scalable, execut...
The "data lake" that was supposed to unify bioprocessing intelligence has, in most companies, become something else entirely: a data swamp, where information goes in and insight rarely comes back out. For anyone trying t...
When AI can draft a literature review in minutes, the question bioprocess educators can no longer avoid is this: what does a student actually need to learn?Steffen Kreye has a clear answer. As Professor of Industrial Bio...
Can aging be fundamentally slowed or even reversed—not by science fiction, but by harnessing the unassuming power of super-early stem cells?In Part 1, Yuta Lee, Founder and CEO of Accelerated Bio, walked through the biol...
What if the key to scalable, off-the-shelf cell therapy was hiding in tissue that surgeons discard every day?Yuta Lee, Founder and CEO of Accelerated Bio, has spent two decades building a cell therapy platform on exactly...
Are you still using one-factor-at-a-time experiments for biosimilar development, losing months, missing interactions, and risking costly dead-ends?In this episode, David Brühlmann, host of the Smart Biotech Scientist Pod...
Are you stuck screening endless compounds in biosimilar development and still not hitting your quality targets? Efficient compound screening is one of the toughest bottlenecks in biopharma, with outdated methods slowing ...
When every batch belongs to a single patient, a single centralized facility cannot serve the world. In Part 2, Chantale Bernatchez moves from process development into the broader consequences of that reality: the manufac...
The most underappreciated parameter in cell therapy process development is not your bioreactor, your media, or your activation protocol. It is the patient. Chantale Bernatchez has spent 20 years learning that lesson the ...
Getting an NDA signed shouldn't take weeks. If your CRO needs more than 48 hours to start the paperwork, your project timeline is already moving in the wrong direction.Ron Najafi knows what rigorous analytical work actua...
When drug safety fails, patients and entire markets pay the price. Understanding your CMC isn't just compliance — it's the line between therapeutic promise and product recall.Ron Najafi has lived that reality firsthand. ...
Completa el formulario de abajo. Asegúrate de seleccionar tanto País como Géneros.
Envíanos un mensaje abajo. Te responderemos en un plazo de 24 horas.